Business Wire

Clarity AI Announces Partnership With Aspiration to Deliver Data-Led Climate and Impact Solutions for Consumer Platforms, as Consumer Demand for Sustainability Grows

26.7.2023 15:00:00 EEST | Business Wire | Press release

Share

Clarity AI, the leading sustainability tech platform announces it has partnered with Aspiration, a top global climate finance company, to launch sustainability assessment solutions for consumer use cases. This unique partnership will deliver effective and accessible solutions to consumer platforms (e.g. e-commerce, retail banks, supermarkets, etc.) to help end users measure and reduce their carbon footprint and understand the sustainability performance of merchants by combining Clarity AI’s high-quality, transparent data and tools with Aspiration’s best-in-class carbon removal projects.

How the climate solution works

Customers will be able to assess the sustainability of the brands they buy and their current spending habits based on Clarity AI’s personalized data tracking and AI capabilities – helping them to identify ways to positively change their purchasing patterns.

Clarity AI’s technology will also provide sustainability insights at the individual retailer level. Leveraging its coverage of over 40,000 companies and more than 160 industries (the broadest in the market), Clarity AI calculates the impact of a consumer’s spending and helps them understand company-specific sustainability information rather than broad, industry-level spending trends. It also provides recommendations on how consumers can maximize the impact of their purchases and actions.

Based on this data, Aspiration will offer customers the opportunity to mitigate their carbon footprint by purchasing credits from high-quality, nature-based climate solutions that are rigorously vetted to deliver real, tangible impact that contributes toward the path to net zero.

Aspiration will also offer customers the opportunity to contribute to carbon removal projects with benefits beyond climate impact such as biodiversity improvements and job creation for underrepresented communities. This approach allows users to support projects that align with their values in broader environmental and social dimensions.

High customer demand for carbon data on purchases and mitigation strategies can be met with high-quality carbon credits

During a recent Clarity AI-hosted event for over 900 global brands (including Citigroup, eBay, and Target), companies revealed which sustainability metrics were most important to their customers.

Amongst the food and beverage, fashion, and electronics sectors – which accounted for 65% of responses – carbon emissions were the most critical metric, with 60% of respondents saying that their customers wanted to see this information. Additionally, 87% of attendees believed sustainability information about consumers’ purchases will be a must-have before 2030, with 44% of them believing it will be a must-have by 2025.

This consumer demand for quality sustainability information is increasing in line with the number of tools available to support sustainability projects, including carbon removals – between 2020 and 2021 the carbon market saw year-on-year growth of 164%.

However, rigorous quality control is critical to driving impact. Aspiration implements best-in-class standards when it comes to vetting carbon removal and avoidance projects – on average, less than one in five projects Aspiration reviews through its diligence process make it into its pipeline of approved projects.

This solution from Clarity AI and Aspiration aims to empower customers to understand the impact of their purchasing decisions and the opportunity for them to take effective action.

Rebeca Minguela, Founder & CEO of Clarity AI commented: “We believe that customers need and want to act, and they need data and tools to do so. They need to seamlessly see the carbon footprint of their purchases and trust that information. Then they need to easily offset those and get recommendations on how to maximize their impact going forward. Partnering with Aspiration, we can satisfy all those criteria and help consumers find a path to a more sustainable future.”

Olivia Albrecht, CEO of Aspiration commented: “The best way to transition to a low-carbon economy is for businesses, consumers, and communities to work collectively to achieve climate goals. The solution we're providing through our collaboration with Clarity AI is all about giving consumers access to climate data and the tools to take action right at their fingertips via their mobile apps.”

About Clarity AI
Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. Clarity AI’s capabilities are an essential tool for end-to-end sustainability analysis related to investing, corporate research, benchmarking, consumer e-commerce, and regulatory reporting. As of June 2023, Clarity AI’s platform analyzes more than 70,000 companies, 420,000 funds, 201 countries, and 199 local governments, which represents more breadth than any other player in the market. One way Clarity AI delivers on its mission to bring societal impact to markets is by ensuring its capabilities are delivered directly into clients' workflows through integrations with partners like BlackRock - Aladdin, Refinitiv an LSEG business, BNP Manaos, CACEIS, and SimCorp. Additionally, Clarity AI's sustainability insights reach more than 150 million consumers across more than 400,000 merchants. Clarity AI has offices in North America, Europe, and the Middle East, and its client network manages tens of trillions in assets and includes companies like Invesco, Nordea, BlackRock, Santander, Wellington, and BNP Paribas.

About Aspiration
Aspiration Partners is a high-impact climate finance company working at scale to help enterprises, consumers, and investors achieve their climate goals. Founded in 2013, the company sources, monitors, and invests in carbon removal projects across the globe to generate high-quality carbon credits. Every project in Aspiration's portfolio is held to the most rigorous standards, ensuring each drives tangible, positive impact for people and the planet. Aspiration is a certified B Corp, a member of Project Drawdown, 1t.org, Climate Pledge and many other critical industry groups dedicated to accelerating climate action. For more information, visit Aspiration.com or Aspiration.com/business.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Edelman
clarityAI@edelmansmithfield.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release

WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be

Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release

Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye